The Ensign Group ENSG Independent subsidiaries with multi-claim reviews scheduled or in process

Other financials

Revenue$1.4B+18.4%

Gross profit$293.4M+19.6%

Operating income$124.9M+23.2%

Net income$99.7M+24.2%

EPS (diluted)$1.67+21.9%

Cash & equivalents$539.5M+90.9%

Total debt$2.2B+11.7%

Total equity$2.4B+22.8%

Total assets$5.6B+17.9%

Operating cash flow$100.2M+38.7%

CapEx$10.0M+27.8%

Free cash flow$90.2M+40.0%

Market cap$8.98B+57.5%

Enterprise value$10.69B+46.4%

P/E24.7×+6.3×

P/S1.7×+0.4×

Gross margin20.6%-0.1pp

Operating margin8.5%0.0pp

Net margin6.9%-0.1pp

FCF margin11%+2.6pp

Return on equity16.9%-0.7pp

Debt / equity0.9×-0.1×

Current ratio1.6×+0.2×

Reported directly by The Ensign Group in its filing.

Tagged under the XBRL concept ensg:IndependentOperatingSubsidiariesUnderMedicareAndMedicaidProbeReviews.

The official record: The Ensign Group’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is The Ensign Group's independent subsidiaries with multi-claim reviews scheduled or in process?: The Ensign Group (ENSG) reported independent subsidiaries with multi-claim reviews scheduled or in process of 22 in Q1 2026.